Literature DB >> 12459624

Prognostic implications of routine, immunohistochemical, and molecular staging in resectable pancreatic adenocarcinoma.

Marco Niedergethmann1, Martin Rexin, Ralf Hildenbrand, Stefanie Knob, Jörg W Sturm, Axel Richter, Stefan Post.   

Abstract

Cure for ductal adenocarcinoma of the pancreas is restricted to resectable tumors, but survival after surgery is still poor. Despite apparently curative resection, these cancers rapidly recur. Thus, the present pathologic examination should be enriched by sensitive methods to detect minimal residual disease. In a prospective setting we studied the frequency of minimal residual disease after curative resection by routine histopathology, immunohistology, and polymerase chain reaction (PCR) for mutated K-ras. Furthermore, the prognostic implication of detecting of MRD was determined. Prospectively, tumor tissue and corresponding paraaortic lymph nodes were obtained from 78 patients, who underwent surgery for pancreatic head tumors between 1999 and 2001. Sixty-nine of 78 cases were diagnosed for ductal adenocarcinoma (study group), whereas nine cases were diagnosed for benign pancreatic tumors (control group). Paraaortic lymph nodes were examined in step sections by routine histopathology (hematoxylin and eosin) and immunohistology using a pan-cytokeratin antibody. DNA of the primary tumor and corresponding paraaortic lymph nodes were analyzed by PCR-based assays with respect to mutated K-ras in codon 12. The recurrence-free survival and overall survival were correlated with the results of the latter methods. In 3 of 69 patients tumor cells were detected in paraaortic lymph nodes by routine histopathology and in 5 of 69 patients by immunohistology. K-ras mutations were detected in 42 of 69 ductal adenocarcinomas (61%), whereas 12 (17%) were positive in paraaortic lymph nodes. All of the latter patients had recurrence after surgery and a significant poorer survival than those without mutated K-ras. Furthermore, paraaortic lymph nodes diagnosed for K-ras mutation were independent prognostic markers in multivariate analysis. In the control group K-ras mutations were detected in one adenoma of Vater's papilla but not in paraaortic lymph nodes. Tumor cell DNA can be detected more sensitively by the described PCR method than with hematoxylin and eosin or immunohistologic staining, leading to a higher sensitivity for detection of micrometastases. The described PCR method clearly determines subgroups of patients after curative resection with early recurrence and poor survival and could therefore enrich the pathologic examination.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12459624     DOI: 10.1097/00000478-200212000-00005

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  17 in total

1.  Immunohistochemically demonstrated lymph node micrometastasis and prognosis in patients with gallbladder carcinoma.

Authors:  Eiji Sasaki; Masato Nagino; Tomoki Ebata; Koji Oda; Toshiyuki Arai; Hideki Nishio; Yuji Nimura
Journal:  Ann Surg       Date:  2006-07       Impact factor: 12.969

2.  Comparison of CT and MRI for presurgical characterization of paraaortic lymph nodes in patients with pancreatico-biliary carcinoma.

Authors:  Young-Chul Kim; Mi-Suk Park; Seung-Whan Cha; Yong-Eun Chung; Joon-Suk Lim; Kyung-Sik Kim; Myeong-Jin Kim; Ki-Whang Kim
Journal:  World J Gastroenterol       Date:  2008-04-14       Impact factor: 5.742

3.  Clinical significance of K-ras and c-erbB-2 mutations in pancreatic adenocarcinoma and chronic pancreatitis.

Authors:  Renata Talar-Wojnarowska; Anita Gasiorowska; Beata Smolarz; Hanna Romanowicz-Makowska; Janusz Strzelczyk; Adam Janiak; Andrzej Kulig; Ewa Malecka-Panas
Journal:  Int J Gastrointest Cancer       Date:  2005

Review 4.  Detection and clinical implications of minimal residual disease in gastro-intestinal cancer.

Authors:  Fabian Wolfrum; Ilka Vogel; Fred Fändrich; Holger Kalthoff
Journal:  Langenbecks Arch Surg       Date:  2005-07-01       Impact factor: 3.445

5.  Impact of lymph node micrometastasis in patients with pancreatic head cancer.

Authors:  Hiroshi Kurahara; Sonshin Takao; Kousei Maemura; Hiroyuki Shinchi; Shoji Natsugoe; Takashi Aikou
Journal:  World J Surg       Date:  2007-03       Impact factor: 3.352

6.  Detection of tumor cell dissemination in pancreatic ductal carcinoma patients by CK 20 RT-PCR indicates poor survival.

Authors:  Edlyn Soeth; Urte Grigoleit; Barbara Moellmann; Christian Röder; Bodo Schniewind; Bernd Kremer; Holger Kalthoff; Ilka Vogel
Journal:  J Cancer Res Clin Oncol       Date:  2005-09-01       Impact factor: 4.553

Review 7.  Pancreatic cancer: a generalized disease--prognostic impact of cancer cell dissemination.

Authors:  D Bogoevski; T Strate; E F Yekebas; J R Izbicki
Journal:  Langenbecks Arch Surg       Date:  2008-01-17       Impact factor: 3.445

Review 8.  Current update on established and novel biomarkers in salivary gland carcinoma pathology and the molecular pathways involved.

Authors:  Markus Stenner; J Peter Klussmann
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-12-04       Impact factor: 2.503

9.  Pancreatic cancer--low survival rates.

Authors:  Hans G Beger; Bettina Rau; Frank Gansauge; Gerd Leder; Michael Schwarz; Bertram Poch
Journal:  Dtsch Arztebl Int       Date:  2008-04-04       Impact factor: 5.594

10.  Comparison of four target volume definitions for pancreatic cancer. Guidelines for treatment of the lymphatics and the primary tumor.

Authors:  E Fokas; C Eccles; N Patel; K-Y Chu; S Warren; W Gillies McKenna; T B Brunner
Journal:  Strahlenther Onkol       Date:  2013-04-05       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.